233 related articles for article (PubMed ID: 19368894)
41. Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b.
Kozono H; Kinoshita T; Kim YU; Takata-Kozono Y; Tsunasawa S; Sakiyama F; Takeda J; Hong K; Inoue K
J Biol Chem; 1990 Aug; 265(24):14444-9. PubMed ID: 2387864
[TBL] [Abstract][Full Text] [Related]
42. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
Pryzdial EL; Isenman DE
J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
[TBL] [Abstract][Full Text] [Related]
43. Structure/function of C5 convertases of complement.
Rawal N; Pangburn MK
Int Immunopharmacol; 2001 Mar; 1(3):415-22. PubMed ID: 11367526
[TBL] [Abstract][Full Text] [Related]
44. FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a.
Inagi R; Miyata T; Maeda K; Sugiyama S; Miyama A; Nakashima I
Immunol Lett; 1991 Jan; 27(1):49-52. PubMed ID: 2019419
[TBL] [Abstract][Full Text] [Related]
45. Covalent binding of C3b to C4b within the classical complement pathway C5 convertase. Determination of amino acid residues involved in ester linkage formation.
Kim YU; Carroll MC; Isenman DE; Nonaka M; Pramoonjago P; Takeda J; Inoue K; Kinoshita T
J Biol Chem; 1992 Feb; 267(6):4171-6. PubMed ID: 1740458
[TBL] [Abstract][Full Text] [Related]
46. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.
Pangburn MK; Müller-Eberhard HJ
Biochem J; 1986 May; 235(3):723-30. PubMed ID: 3638964
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of complement activation by crystalline cholesterol.
Vogt W; von Zabern I; Damerau B; Hesse D; Lühmann B; Nolte R
Mol Immunol; 1985 Feb; 22(2):101-6. PubMed ID: 3156272
[TBL] [Abstract][Full Text] [Related]
48. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
Parker CJ; White VF; Falk RJ
Complement; 1986; 3(4):223-35. PubMed ID: 3643079
[TBL] [Abstract][Full Text] [Related]
49. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
[TBL] [Abstract][Full Text] [Related]
50. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).
Bexborn F; Andersson PO; Chen H; Nilsson B; Ekdahl KN
Mol Immunol; 2008 Apr; 45(8):2370-9. PubMed ID: 18096230
[TBL] [Abstract][Full Text] [Related]
51. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
52. Activation of complement component C5: comparison of C5 convertases of the lectin pathway and the classical pathway of complement.
Rawal N; Rajagopalan R; Salvi VP
J Biol Chem; 2008 Mar; 283(12):7853-63. PubMed ID: 18204047
[TBL] [Abstract][Full Text] [Related]
53. Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D.
Hong K; Kinoshita T; Pramoonjago P; Kim YU; Seya T; Inoue K
J Immunol; 1991 Mar; 146(6):1868-73. PubMed ID: 2005382
[TBL] [Abstract][Full Text] [Related]
54. Coexistence of closed and open conformations of complement factor B in the alternative pathway C3bB(Mg2+) proconvertase.
Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
J Immunol; 2009 Dec; 183(11):7347-51. PubMed ID: 19890040
[TBL] [Abstract][Full Text] [Related]
55. Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models.
Zwarthoff SA; Berends ETM; Mol S; Ruyken M; Aerts PC; Józsi M; de Haas CJC; Rooijakkers SHM; Gorham RD
Front Immunol; 2018; 9():1691. PubMed ID: 30083158
[TBL] [Abstract][Full Text] [Related]
56. Structure-Guided Engineering of a Complement Component C3-Binding Nanobody Improves Specificity and Adds Cofactor Activity.
Pedersen H; Jensen RK; Hansen AG; Petersen SV; Thiel S; Laursen NS; Andersen GR
Front Immunol; 2022; 13():872536. PubMed ID: 35935935
[TBL] [Abstract][Full Text] [Related]
57. Engineering of human complement component C3 for catalytic inhibition of complement.
Kölln J; Bredehorst R; Spillner E
Immunol Lett; 2005 Apr; 98(1):49-56. PubMed ID: 15790508
[TBL] [Abstract][Full Text] [Related]
58. Autoantibodies Against C3b-Functional Consequences and Disease Relevance.
Vasilev VV; Radanova M; Lazarov VJ; Dragon-Durey MA; Fremeaux-Bacchi V; Roumenina LT
Front Immunol; 2019; 10():64. PubMed ID: 30761135
[TBL] [Abstract][Full Text] [Related]
59. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
60. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
Takata Y; Kinoshita T; Kozono H; Takeda J; Tanaka E; Hong K; Inoue K
J Exp Med; 1987 Jun; 165(6):1494-507. PubMed ID: 3495629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
